MYC and bone sarcoma: In bone sarcomas, MET amplification (hazard ratio [HR] = 0.17, 95% confidence interval [CI]: 0.05–0.51, p < 0.001) or MYC amplification (HR = 0.2, 95% CI: 0.07–0.55, p < 0.001) were significantly associated with worse overall survival (Figures 6B, C).